Cargando…
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
BACKGROUND: Prospectively collected, routine clinical practice-based data on antithrombotic therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world comparative outcomes. The objective was to compare the safety and effectiveness of dabigatran versus vitamin K...
Autores principales: | Huisman, Menno V., Teutsch, Christine, Lu, Shihai, Diener, Hans-Christoph, Dubner, Sergio J., Halperin, Jonathan L., Ma, Chang-Sheng, Rothman, Kenneth J., Lohmann, Ragna, Gurusamy, Venkatesh Kumar, Bartels, Dorothee B., Lip, Gregory Y. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054866/ https://www.ncbi.nlm.nih.gov/pubmed/35294623 http://dx.doi.org/10.1007/s00392-021-01957-1 |
Ejemplares similares
-
Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry
por: Ma, Changsheng, et al.
Publicado: (2020) -
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
por: Lip, Gregory Y. H., et al.
Publicado: (2022) -
Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF
por: Dubner, Sergio J., et al.
Publicado: (2020) -
Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
por: Lip, Gregory Y. H., et al.
Publicado: (2022) -
Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF
por: Kozieł, Monika, et al.
Publicado: (2021)